開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT COMPLETION OF PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL OF GT20029 FOR TREATMENT OF ANDROGENETIC ALOPECIA IN CHINA

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the enrollment of 180 patients has been completed for the China phase II clinical trial (the "**Phase II Clinical Trial**") of its in-house developed first-in-class proteolysis targeting chimera ("**PROTAC**") compound GT20029 for the treatment of male androgenetic alopecia ("**AGA**"). GT20029 was developed based on the in-house PROTAC platform of the Company and is the first topical PROTAC compound which has entered the phase II clinical stage worldwide.

The Phase II Clinical Trial is a multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of GT20029 for treating male AGA patients in China, and to determine the recommended dosage for phase III clinical trial. This trial involves a total of 12 clinical research centers in China, and Professor Yang Qinping (楊勤萍) from Fudan University Huashan Hospital (復旦大學附屬華山醫院) is the leading principal investigator (leading PI). The primary endpoint of this trial is the change from baseline in non-vellus target area hair counts ("**TAHC**") after 12 weeks of treatment in comparison to placebo.

The first patient enrollment in the Phase II Clinical Trial took place in April 2023, and the enrollment of all patients is completed in about four months, and the top-line data readout is expected in the first quarter of 2024. Previously, the Company has completed the phase I clinical trials of GT20029 both in China and the US, and the top-line data of more than 200 subjects has demonstrated that GT20029 has a good safety profile and is well-tolerated for single and multiple doses of topical application. For details, please refer to the announcements of the Company dated 24 November 2022, 10 February 2023 and 14 April 2023, respectively.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GT20029 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman, Executive Director and Chief Executive Officer

Hong Kong, 22 August 2023

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong, Dr. Qun Lu and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*